Feeding EPA and DHA Improve Clinical Symptoms Associated with COVID-19 Infection

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:1 publications

Grant number: 174885

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2021
    2022
  • Known Financial Commitments (USD)

    $271,957.5
  • Funder

    Canadian Institutes of Health Research (CIHR)
  • Principal Investigator

    Vera C Mazurak
  • Research Location

    Canada
  • Lead Research Institution

    University of Alberta
  • Research Priority Alignment

    N/A
  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Prognostic factors for disease severity

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The purpose of this study is to find out if the amount of a certain type of fat in the body, called n-3 fatty acids, is related to the severity of COVID-19 symptoms. Currently, it is known that higher amounts of n-3 fatty acids improve outcomes in some conditions. This study will test whether increasing n-3 fatty acids through a medical food improves the clinical outcomes and severity of COVID-19 infection. Patients admitted to the ICU will be randomized to receive a medical food containing n-3 fatty acids or one without. Blood samples will drawn at specific points during the care of patients who have COVID-19. These blood samples will be examined for fatty acids and level of inflammation. Clinical data regarding symptoms and progression or resolution of disease will be collected from patients medical records. Groups will be compared on level of n-3 fatty acids and the association with inflammation, symptoms and disease progression. We hope this study will lead to simple treatment options involving nutritional strategies designed to significantly raise the individual patient's plasma n-3 fatty acid levels.

Publicationslinked via Europe PMC

Last Updated:an hour ago

View all publications at Europe PMC